No. metastases | 1-year actuarial OS (%) | Median OS (months) | Univariate p value | Multivariate p value | |
---|---|---|---|---|---|
Gender | 0.955 | ||||
male | 55 | 35 | 9.9 | ||
female | 53 | 33 | 9.1 | ||
Age | 0.777 | ||||
< 57.5 years (median) | 54 | 44 | 9.9 | ||
≥ 57.5 years (median) | 54 | 24 | 6.3 | ||
NSCLC vs. Others | 0.778 | ||||
NSCLC | 43 | 40 | 7.2 | ||
others | 65 | 32 | 10.7 | ||
RPA | 0.010 | ||||
I | 36 | 50 | 11.8 | ||
II | 72 | 28 | 4.7 | ||
Extracerebral activity of primary tumor | 0.001 | 0.001 | |||
not detectable | 30 | 47 | 11.7 | ||
stable | 25 | 48 | 10.0 | ||
progredient | 53 | 23 | 4.0 | ||
Objective of therapy | 0.217 | ||||
primary | 52 | 37 | 8.9 | ||
recurrence | 56 | 34 | 10.0 | ||
Steroid uptake | 0.005 | 0.030 | |||
yes | 51 | 18 | 5.4 | ||
no | 57 | 51 | 13.0 | ||
GTV | 0.004 | 0.019 | |||
< 2 ccm | 57 | 49 | 11.5 | ||
≥ 2 ccm | 51 | 20 | 5.4 | ||
EQD2 (35 Gy) | 0.021 | 0.298 | |||
≤ 35 Gy | 24 | 13 | 3.6 | ||
> 35 Gy | 84 | 42 | 10.7 | ||
EQD2 (median 39 Gy) | 0.009 | 0.012 | |||
< 39 Gy | 54 | 26 | 7.2 | ||
≥ 39 Gy | 54 | 44 | 11.5 | ||
V4 Gy (median 16.7 ccm) | 0.271 | ||||
< 16.7 ccm | 56 | 32 | 7.2 | ||
≥ 16.7 ccm | 52 | 38 | 9.1 | ||
Time between diagnosis of primary and diagnosis of brain metastases | 0.092 | ||||
< 12.5 months | 52 | 30 | 9.1 | ||
≥ 12.5 months | 56 | 40 | 8.9 |